Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40ZST | ISIN: US59267L1070 | Ticker-Symbol:
NASDAQ
24.04.25
21:59 Uhr
21,280 US-Dollar
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
METSERA INC Chart 1 Jahr
5-Tage-Chart
METSERA INC 5-Tage-Chart

Aktuelle News zur METSERA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.04.Why did Lilly data for oral GLP-1 boost Structure and Metsera?9
METSERA Aktie jetzt für 0€ handeln
14.04.Viking, Structure, Metsera on a tear as Pfizer drops obesity pill5
27.03.Metsera reports Q4 results5
26.03.Metsera, Inc. - 10-K, Annual Report2
26.03.Metsera, Inc. Q4 Loss Rises1
26.03.Metsera, Inc. - 8-K, Current Report-
26.03.Metsera, Inc.: Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress744MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and...
► Artikel lesen
15.03.Metsera, Inc. (MTSR): Among Top Insider Purchases Last Month2
10.03.Metsera, Inc. - 8-K, Current Report2
04.03.Why Did MTSR Stock Surge 15% On The Worst Trading Day Of 2025? Here's What Has Happened Since Its Listing1
27.02.CenExel Research: CenExel Supports Metsera, Inc. in Successful Phase II Trial of MET-097 for Obesity and Metabolic Diseases339SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 / CenExel is pleased to announce its partnership with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing treatments...
► Artikel lesen
25.02.Metsera started by Guggenheim at buy on obesity drug opportunity2
25.02.Wall Street bullish on Metsera following January IPO on obesity drug pipeline1
25.02.Metsera started at buy at Guggenheim on obesity treatment potential1
25.02.Cantor Fitzgerald initiates Metsera with overweight rating1
25.02.BofA sets Metsera stock Buy rating, $38 price target3
25.02.Guggenheim sets Metsera stock Buy rating, $56 target1
05.02.Metsera, Inc.: Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares195NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) ("Metsera"), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone...
► Artikel lesen
04.02.Metsera, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
03.02.Metsera, Inc. - 8-K, Current Report-
Seite:  Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1